Allergy Therapeutics
plc
("Allergy
Therapeutics" or the "Company")
Notice of 2023 Annual General
Meeting
09
February 2024 Allergy Therapeutics
plc (AIM: AGY), the fully integrated commercial biotechnology
company specialising in allergy vaccines, has today published its
Notice of 2023 Annual General Meeting. It is available
electronically on the Company's website at
https://www.allergytherapeutics.com/investors/shareholder-services/agm-information/.
A hard copy of the Notice of Meeting
has been posted to shareholders on 9 February 2024.
- ENDS
-
For
further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
Panmure Gordon (Nominated Adviser and
Broker)
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl,
Corporate Finance
Rupert Dearden, Corporate
Broking
ICR
Consilium
+44 20 3709 5700
Mary-Jane Elliott / David Daley /
Davide Salvi
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that
have the potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
includes vaccines for grass, tree, house dust mite and peanut. For
more information, please see www.allergytherapeutics.com.